Objective: To determine fatty acid levels in the US donor milk supply.
Introduction
Long-chain polyunsaturated fatty acids (LCPUFA) including docosahexaenoic acid (DHA) and arachidonic acid (ARA), are essential for normal growth, neurodevelopment and health. [1] [2] [3] Preterm infants are relatively deficient in these essential fatty acids and have a higher incidence of neurodevelopmental problems later in life. [4] [5] [6] Furthermore, animal and epidemiological data suggest that DHA has a protective role in the prevention of bronchopulmonary dysplasia, retinopathy of prematurity and necrotizing enterocolitis, all associated with significant morbidity and mortality in these infants. [7] [8] [9] [10] [11] During the last trimester when a fetus undergoes rapid growth and brain development, maternal and fetal DHA levels are high, allowing increased incorporation into tissues. 1, 3, 12, 13 Infants born before this process is complete have interruption in the normal LCPUFA accretion. In very preterm infants this deficit persists due to decreased fat stores, poor nutritional provision and ongoing inability to convert precursor fatty acids to ARA and DHA in vivo.
14 For these reasons, a postnatal dietary source is even more critical to support normal growth, neurodevelopment and health of this at-risk population. [15] [16] [17] [18] [19] [20] Mother's own milk is the optimal diet because of its many benefits including the provision of essential fatty acids. Further advantages of human milk in extremely low-birth weight (ELBW) infants include decreased risks of infection, necrotizing enterocolitis and feeding intolerance. [21] [22] [23] Mother's own breastmilk is not available to all preterm infants in the Neonatal Intensive Care Unit (NICU). Alternatives include pasteurized donor human milk or ARA/DHA-supplemented formula. Because of its recognized benefits and increasing availability, pasteurized donor human milk is increasingly used for preterm infants in the NICU. 23 LCPUFA concentrations in the US donor milk supply and the effect of pasteurization on these nutrients are not well studied. The specific aims of this study were to analyze the effects of Holder pasteurization on LCPUFA content and to determine the variance of ARA and DHA among multiple US donor milk banks to further assess LCPUFA provision from this neonatal nutrition option.
Methods

Donor human milk collection before and after pasteurization
Under the approval of the University of Iowa's Institutional Review Board, samples of pooled donor breastmilk from the Mother's Milk Bank of Iowa (MMBI) were collected for analysis before and after the Holder pasteurization. Donors remained anonymous and samples were analyzed only if each donor consented to the use of their milk for research purposes. Milk was donated frozen within 6 months of expression. By usual protocol, donor human milk was pooled in batches from 3 to 10 donors. Thereafter, pooled milk was processed via Holder pasteurization at 62 1C for 30 min, according to the standards published by the Human Milk Banking Assoc of North America (HMBANA). 24 For our study, 1 ml of thawed, pooled donor human milk was collected before pasteurization in 2 ml amber glass vials with Teflon-coated caps. A corresponding sealed bottle of donor human milk was obtained from the same pooled batch after pasteurization. All samples were frozen at À20 1C until processing.
Fatty acid analysis
Direct transesterification of milk samples was accomplished within 30 days of collection as described by LePage. 25 Thawed, 0.1 ml milk samples were pipetted into glass vials with Teflon caps. A total of 1 ml of methanol:benzene 3:2 (v:v) containing 0.5 mg per ml of 17:0 heptadecanoic acid as internal standard and 1 ml of freshly prepared acetylchloride:methanol 5:100 (v:v) were added to each tube. Methanolysis at 95 to 100 1C for 1 h was performed to create fatty acid methyl esters. A total of 1 ml of distilled water and 1 ml of hexane with 0.5 mg per ml 15:0 methylpentadecanoate as external standard were added. Samples were centrifuged and stored at 4 1C until analysis by gas chromatography. A total of 1 ml of the fatty-acid methyl ester containing upper phase was injected onto an HP5890 GC equipped with a Sigma Aldrich Omegawax 250 Capillary Column (Sigma Aldrich, Bellefonte, PA, USA) (30 m Â 0.25 mm Â 0.25 mm film thickness.) Nitrogen was the carrier gas. Fatty acids of carbon length from 12 to 24 were detected by flame ionization. A Gilson 506C interface system (Middleton, WI) recorded the data. Fatty-acid methyl ester peaks were identified using 37 fatty-acid methyl ester mix authentic standard (Sigma Aldrich) and integrated using Unipoint 3.0 Software (Gilson, Middleton, WI), to report peaks on a wt:wt% basis.
HMBANA donor milk sample collection and analysis Pasteurized milk from other HMBANA banks was analyzed to determine the variability of these nutrients in the US donor milk supply. With Institutional Review Board approval, milk samples were obtained from The Mother's Milk Bank at Austin (Texas, n ¼ 5), WakeMed Mother's Milk Bank (North Carolina, n ¼ 5) and The Mother's Milk Bank (San Jose, CA, USA, n ¼ 5). Samples of pooled, pasteurized and frozen donor human milk were shipped on dry ice and stored at À20 1C until analysis. The Mother's Milk Bank of Austin provided donor human milk samples in three caloric concentrations: 20 kcal per oz (n ¼ 2), 22 kcal per oz (n ¼ 2) and 24 kcal per oz (n ¼ 1). Milk from the other HMBANA banks was not routinely tested for nutrient content but assumed to be 20 kcal per oz. Samples were analyzed by the same methodology described above.
ARA and DHA analysis of infant formula and maternal human milk samples To allow direct comparison between formula, mother's own milk and donor breastmilk, we subjected samples (n ¼ 2) of Enfamil Lipil (Mead Johnson, Evansville, IN, USA) and maternal human milk samples (n ¼ 6) to the same methodology as our donor milk samples. To simulate the feeding experience of most ELBW infants in the NICU, the human milk samples were collected from individual mothers in Iowa at the time of pumping and frozen at À20 1C for greater than 2 weeks, thawed and then processed by the aforementioned analysis in a blinded fashion. Because these were anonymous samples from individual mothers living in Iowa, maternal factors other than the region of residence are not reported.
Statistical analysis
The fatty acid content was reported as mean wt:wt% of each sample ± the s.d. Data were analyzed using a paired t-test for pre-and post-pasteurized human milk comparisons, defining significance at P<0.05. Non-parametric testing was also completed for LA due to a few outlying data points but revealed unchanged results. Variability of the fatty acid levels in donor human milk between different batches and poolings over time was evaluated by calculating mean, median, range and coefficient of variation for individual fatty acids using 62 samples from 31 batches and 32 donors collected over a 15-month period from the MMBI. LCPUFA levels among various HMBANA banks were compared via analysis of variance using the same level of significance (P<0.05).
Results
Effects of pasteurization on fatty acid content
To study the effects of pasteurization on LCPUFA content in breastmilk, 31 samples of pooled, donor human milk from the MMBI were analyzed before and after the Holder pasteurization. Mean wt:wt% (s.d.) of ARA, DHA and their respective precursors LA and ALA, are reported in Table 1 . Other than a 3-% decrease in ALA (P ¼ 0.04), there was no significant difference in fatty acid composition with pasteurization of donor human milk. Relative concentrations of LA, ARA and DHA did not change with Holder pasteurization.
Variability of fatty acid content across poolings over time Utilizing the methodology outlined above, 62 samples of pooled donor human milk from the MMBI were collected and analyzed for DHA analysis of infant formula and maternal human milk samples Post-hoc analysis of infant formula and mother's own milk was done for the comparison of DHA content with donor human milk. Enfamil Lipil revealed DHA levels (0.30 wt:wt%) similar to the published product information (0.32 wt:wt%). Maternal milk from individual mother's in Iowa was analyzed after pumping, freezing and thawing to simulate the process used for most feedings in the NICU. The average DHA content (0.08 ± 0.03 wt:wt%) was similar to that found in the donor human milk from the same region (MMBI). However, individual variation was much greater in these non-pooled samples with a range from 0.03 to 0.21 wt:wt%.
Discussion
Using a large number of samples from the MMBI, we found that Holder pasteurization does not significantly affect ARA or DHA levels in then donor human milk. We also determined that LCPUFA levels are consistent at a single bank between batches of pooled donor milk over time. However, DHA levels in Iowa breastmilk were much lower than expected, prompting a smaller scale comparison that revealed significant differences in DHA levels among milk banks from different regions of the US. Overall, DHA content in the US donor human milk supply does not meet the recommended dietary provision for infants 26 nor does it approximate what is needed to replenish the deficit found in premature infants. 14, 27 Congruent with the published findings, [28] [29] [30] pasteurization did not alter the LCPUFA levels in donor human milk. Our study builds on smaller studies that evaluated the effects of Holder pasteurization on human breastmilk in 6 to 12 samples, mostly from individual donors. Because HMBANA banks routinely pool donor human milk before pasteurization to decrease individual variation of nutrients, our study compared only pooled donor human milk samples. Additionally, we used a larger number of samples and determined the variability of LCPUFA levels in pooled donor milk from a single milk bank (MMBI) over a 15-months time. This information has not been previously reported in the literature, and is important because DHA content in breastmilk varies significantly among individual mothers with time. 31 Our results show that pooling donor milk limits variation from batch to Fatty acid levels in US donor human milk ML Baack et al batch over time. Therefore, we conclude that the pooling and pasteurization process used by HMBANA results in a product containing consistent quantities of LCPUFA in milk dispensed from the individual banks. Although HMBANA processing created consistent LCPUFA concentrations in dispensed donor human milk, we demonstrated that DHA, but not ARA levels, varied significantly between the individual banks. This was not entirely surprising because DHA varies in expressed breastmilk based on multiple maternal characteristics including timing of expression, dietary and regional factors. 32 Among the banks studied, Iowa had the lowest (0.07 wt:wt%) and Texas had the highest (0.20 wt:wt%) DHA content. Because Texas submitted donor milk samples with increasing caloric content, the mean level may be falsely elevated. If only 20 kcal per oz milk from Texas was included (0.14 wt:wt%) there would be less, but still significant, variation in DHA among the studied banks. Nonetheless, DHA levels in pasteurized donor milk from Texas, North Carolina and California, which are in nearer proximity to the coast, were higher than the donor milk from Iowa. The Mother's Milk Bank of Ohio, another inland location, reported DHA levels in donor milk that were closer to those found in Iowa. 30 We speculate that the donor population of Iowa consumes smaller amounts of omega-3-laden fish than do the donors in more coastal areas, due to limited availability and higher cost of these fish in the Midwest. Also, prenatal vitamins prescribed in Iowa during the time of this study were not typically enriched with omega-3 fatty acids.
Despite regional variation, mean DHA content measured in donor milk samples from all the HMBANA banks studied (from 0.07 to 0.20 wt:wt%) was lower than mean levels reported in other neonatal nutrition options. An illustrative comparison of these differences is represented in Figure 1 . Current recommendations for DHA intake in all infants is based on a worldwide mean DHA content in expressed breastmilk, as published by Brenna et al. 26, 32 This meta-analysis of 65 studies, including 2474 women from 34 countries, showed a worldwide mean DHA level in breastmilk of 0.32 ± 0.22 wt:wt%, with notable regional variation ranging between 0.06 to 2 wt:wt%. Several banks (Texas, North Carolina and California) had DHA content congruent with published North American means (0.14 wt:wt%). 32 The Iowa levels were 50% lower, similar to those found in expressed breastmilk in rural Pakistan. 33 Currently, DHA is added to most infant formula in the range of 0.14 to 0.32 wt:wt%.
Overall, pasteurized donor human milk from all banks studied had DHA content lower than the the worldwide mean found in maternal breastmilk. We speculate that the DHA content in donor human milk is low, in part, because of inherent systematic factors. Women who donate breastmilk have typically been lactating for several months at the time of donation, thus further removed from when maternal levels peak in the third trimester of pregnancy. 34 Donors in Iowa have been lactating for an average of 6 to 12 months at the time of donation, which may contribute to lower DHA content. 21, 35, 36 In all HMBANA banks, breastmilk can be donated frozen up to 6 months after the expression. Another source of low DHA may be freezing and storing expressed breastmilk, which may allow degradation of DHA. 21, 32 DHA levels in human milk from individual Iowa mothers, evaluated after expression, storing and freezing were similar to samples from the MMBI, possibly consistent with freezing and storage as a source of DHA loss, though shared maternal characteristics with donors is also possible. It is estimated that ELBW infants need 17 mg per kg per d or 1.5% of fatty acid intake as DHA to catch up from the relative deficiency at birth, which worsens in the first month of life with current neonatal nutrition regimens.
14 No current neonatal nutrition option, including donor human milk, alone can meet the needs of this at-risk population.
Limitations of our study include the inability to assess donor characteristics for each pooled batch of milk. Confounding factors, such as dietary characteristics, days of lactation, length of time since pregnancy, time of expression or the specific storage conditions for donor milk or maternal milk samples are not known. Although there seemed to be a regional difference between Iowa and other studied HMBANA milk banks, the sample size from non-Iowa banks was limited increasing the risk of Type II error. Although the sample sizes from milk banks other than the MMBI were small, these samples were pooled and pasteurized, but not from individual mothers. Because this study shows that pooling milk provides consistent LCPUFA levels between the batches over time, these samples can be considered representative of regional Fatty acid levels in US donor human milk ML Baack et al differences rather than individual donor differences, substantiating previously published regional variation reported in mother's own milk from various places around the world. 32 In conclusion, with the exception of a minor decrease in ALA, Holder pasteurization does not affect LCPUFA content of donor human milk. As is true with mother's own milk, DHA levels vary significantly between milk banks, but ARA levels do not. Donor human milk has lower DHA content than worldwide levels of mother's own milk or formula, and does not meet the recommended nutritional guidelines for optimal provision of LCPUFA to infants. Furthermore, without supplementation the average DHA provision from donor human milk in this study (0.14 wt:wt%) provides one tenth of the estimated needs of ELBW infants in the NICU.
14 Despite low DHA levels, donor human milk provides other health benefits to ELBW infants in the NICU over formula, 21, 37 making it an increasingly popular alternative for very preterm infants. 23 To provide adequate growth for this population of patients, donor human milk is typically fortified to provide more calories, protein, calcium and phosphorous. Given the growing body of evidence about the importance of LCPUFAs in neonates, the addition of DHA to fortification of donor human milk should be further studied to support the overall health and neurodevelopment of this at-risk population.
